The cytogenetic evolution of the prostatic adenocarcinoma cell line LNCaP was investigated during long term in vitro culture. Study of five different sublines demonstrated that the original karyotype was well preserved in all sublines, with respect to the chromosome number as well as to the primary markers. All sublines showed additional, subline specific secondary marker chromosomes. Comparison of these markers in androgen responsive and nonresponsive sublines showed rearrangement of the short arm of chromosome 8 in both unresponsive sublines. The breakpoints were in 8p21 and 8p23, respectively, resulting in deletion of the 8p23----pter region in both sublines. In contrast, the hormone responsive sublines did not show any aberrations in chromosome 8. Review of published karyotypes of patients and cell lines seems to support our finding of partial deletion of 8p in androgen unresponsive prostate tumor cells.
The effects of prostate fibroblast conditioned medium on two prostate epithelial cell lines (PC-3, LNCaP) and on two non-prostatic cell lines (MCF-7, K562) was investigated. As prostate fibroblast conditioned medium exerts its main effect on DNA synthesis, 3H thymidine incorporation was monitored to measure factor activity. Conditioned media of all prostatic fibroblast lines investigated were inhibitory for PC-3, LNCaP and MCF-7. Conditioned medium of prostatic fibroblasts was clearly stimulatory for K562. Prostate specificity of production of PEIF was demonstrated by the fact that conditioned medium from skin fibroblasts proved to be stimulatory for PC-3. Inhibitory activity from conditioned medium as well as from a BPH homogenate was precipitated by 33-67% ammonium sulfate. These partly purified fractions were respectively five and ten times as active as "crude" conditioned medium. The physical nature of PEIF (protein or macroglycolipid) as well as the possible function (as a signal messenger between stroma and epithelium) is discussed.
Interactive at www.nejm.org C a se Vigne t teA 63-year-old man who has been under your care for the past 3 years undergoes an annual check-up. He believes he is in excellent health, and he has no medical problems to report. In 2006, his physical examination and routine laboratory tests were normal, and the prostate-specific antigen (PSA) level was 1.5 ng per milliliter. There had been no new findings in 2007, except that the PSA level had risen to 3.1 ng per milliliter. This year's annual check-up reveals a PSA level of 3.8 ng per milliliter, and a digital rectal examination is normal. Concerned about the rising PSA level, you refer the patient to a urologist, who performs ultrasonography and biopsy of the prostate. The prostate volume is 22 cm 3 , and of 12 biopsy cores, 2 (10% of one and 20% of another) show involvement with adenocarcinoma, with a Gleason score of 6.The patient, a widower with normal sexual function, plans to continue to run his advertising business. He does not smoke, drinks only occasionally, and jogs 2 miles three times a week. He Tre atment Op tion 1 This interactive feature addresses the diagnosis or management of a clinical case. A case vignette is followed by specific clinical options, none of which can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. In the online version of this feature, available at www.nejm.org, readers can participate in forming community opinion by choosing one of the options and, if they like, providing their reasons. The New England Journal of Medicine Downloaded from nejm.org at NYU WASHINGTON SQUARE CAMPUS on June 1, 2015. For personal use only. No other uses without permission.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.